Valion Bio (VBIO) Total Current Liabilities (2021 - 2026)

Valion Bio has reported Total Current Liabilities for 6 years, with the latest figure at $3.0 million in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 271.01% year-over-year to $3.0 million in Q2 2026; TTM through Jun 2026 was $3.0 million, a 271.01% increase from a year earlier, with the FY2025 full-year figure at $646000.0, up 137.5% from the prior year.
• Total Current Liabilities was $3.0 million for Q2 2026 at Valion Bio, up from $646000.0 in the prior quarter.
• The five-year high for Total Current Liabilities was $3.0 million in Q2 2026, with the low at $272000.0 in Q4 2024.
• Average Total Current Liabilities over 5 years is $1.2 million, with a median of $1.0 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2026: Total Current Liabilities slumped 80.59% in 2024, then jumped 271.01% in 2026.
• Over 5 years, Total Current Liabilities stood at $1.9 million in 2022, then retreated by 25.4% to $1.4 million in 2023, then plunged by 80.59% to $272000.0 in 2024, then soared by 137.5% to $646000.0 in 2025, then surged by 371.52% to $3.0 million in 2026.
• The last three Total Current Liabilities figures came in at $3.0 million (Q2 2026), $646000.0 (Q4 2025), and $638000.0 (Q3 2025), per Business Quant data.